Home
Life Sciences
Pharmaceutical
Drug and Medication
MarketVIEW: Chlamydia trachomatis vaccines

MarketVIEW: Chlamydia trachomatis vaccines

$ 8 995 - June 2012 - by VacZine Analytics Group Of Assay Advantage Ltd - 65

Summary

Table of Contents

View Report

Search Inside

Data Series

Industry

Drug and Medication

Country

Europe
China
India
Japan
Germany
France
Italy
Russian Federation
Spain
United Kingdom
Canada
Mexico
United States
Brazil
World
Australia

Keywords

Hpv Vaccine
Adolescent Vaccine
Antibiotic
Vaccine

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Contents – Summary presentation (MS PowerPoint based)
Executive Summary
Commercial model – key outputs
Total available demand: Chlamydia vaccine, global, (000s doses)
Total available demand: Chlamydia vaccine, high-income markets, (000s doses)
Total available demand: Chlamydia vaccine, emerging markets, (000s doses)
Total available market: Chlamydia vaccine, global, ($ 000s)
Total available market: Chlamydia vaccine, by market, ($ 000s)
Total available market: Chlamydia vaccine, price sensitivity analysis, ($ 000s)
Chlamydia vaccine: country volume analysis, 2025 (000s doses)
Chlamydia vaccine: country value analysis, 2025 ($ 000s)
The role of a CT vaccine
Commercial model – key assumptions
Pricing
Model forecast comparisons: June 2011 v current
Chlamydia vaccine opportunity: target product profile
Overall commercial model assumptions per country
Chlamydia trachomatis: brief background
Clinical features
Chlamydia trachomatis: natural history of infection
Chlamydia trachomatis: global incidence
Chlamydia trachomatis: global prevalence
US epidemiology
UK epidemiology
Reasons for increasing incidence
Potential impact of a CT vaccine
Competitor landscape: overview
Competitive environment: major players
Chlamydia trachomatis vaccine – HPV, a relevant case study?
HPV vaccines: analysis of country uptake
Bibliography
Disclaimer
About VacZine Analytics

PAGES: ~57 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)
Title Sheet
Scenario definition
Value Scenario Analysis
Value Summary (Western)
Volume Summary (Western)
Value Summary (Emerging)
Volume Summary (Emerging)
Charts – volume (Western)
Charts – value (Western)
Charts – value/volume (Western)
Females (Western) ?
US (13 yrs/ 14 - 18 yrs)
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Japan
Females (Emerging) ?
Brazil
Russia
India
China
Mexico
Population database
Competition – IP landscape
Assumptions – major markets
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65

Drug and Medication in Europe

Portugal Pharmaceutical Sales, Us$bn, % Chg Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

Industries : Drug and Medication
Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Eurbn, % Chg Y-o-y

$ 250
Industry data
January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

Industries : Drug and Medication
Countries : Portugal, Europe

Portugal Pharmaceutical Sales At Constant Exchange Rate, Us$bn

$ 250
Industry data
January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

Industries : Drug and Medication
Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Us$ Per Capita

$ 250
Industry data
January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

Industries : Drug and Medication
Countries : Portugal, Europe

Portugal Pharmaceutical Sales, % Of Gdp

$ 250
Industry data
January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

Industries : Drug and Medication
Countries : Portugal, Europe

BUY THIS REPORT

ASK INFO SPECIALIST 24/7

Robyn - online now

00 1 718 213 49 04

Send Message @Robyn

Drug And Medication Industry in Europe : Latest Reports

Vaccines - Global Markets Package

$ 24 060
Industry report
May 2013
by Global Research & Data Services

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market ...

Infertility Drugs And Devices Market - Global Industry Analysis, Size, Share And Forecast, 2010 - 2017

$ 4 395
Industry report
November 2013
by Transparency Market Research

This report is an effort to identify factors, which will be the driving force for the infertility drugs and devices market and sub-markets in the next few years. The report provides an extensive analysis ...

Triple Analysis: Angiogenesis, Cancer Vaccines and Peptides

$ 5 175
Industry report
March 2013
by Bioseeker

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three ...

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Angiogenesis, Cancer Vacc ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Angiogenesis A ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Apoptosis, Cancer Vaccine ...

March 2013 $ 5 175

Triple Analysis: Breast Cancer, Angiogenes ...

March 2013 $ 5 175

More Reports:

Drug and Medication in China (129)

Drug and Medication in France (47)

Drug and Medication in Germany (47)

Drug and Medication in Italy (45)

Drug and Medication in Japan (61)

Drug and Medication in Spain (42)

Drug and Me... in the United Kingdom (48)

Drug and Me... in the United States (151)

Company Reports

GlaxoSmithKline P.L.C.

Novartis Inc.

Pfizer Inc.

Johnson And Johnson

GlaxoSmithKline PLC

Eli Lilly And Co.

AstraZeneca PLC

Lilly And Co.

Sanofi-Aventis Senegal

Bristol-Myers Squibb Co.

Drug And Medication Industry in Europe : Latest Downloads

Drug and Medication Industry Analysis

Industry report
April 2013
53 pages

... Use internally as part of a monthly cleansing regimen for gi health antibiotic, anti-inflammatory, antibacterial, antifungal, antioxidant, anti-parasitic, antiviral, disinfectant candida cleanse ...

Drug and Medication Market Brief

Industry report
April 2013
18 pages

... Antiosteoporosic drugs - casula m, filippi a, flacco e, gambera m, manzoli l, menditto e, orlando v, piccinelli r, tragni e, catapano a. Assessment and potential determinats of compliance and persistence to anti ...

Drug and Medication : Innovation and Technology Trends

Industry report
April 2013
12 pages

... Clinical regulatory toxicology phase i clinical phase ii clinical diabetes inflammation oncology (non-cytotoxic) anti-infectives clotting disorders obesity cns nce pipeline nce pipeline tyrosine-tzd, non ...